Photo via TIME

The Next Chapter of mRNA

Read the original at TIME ↗
Cite

Park, A. (2026, November 12). The Next Chapter of mRNA. TIME. https://time.com/article/2026/11/12/next-chapter-of-mrna-moderna-stephane-bancel/

Dated from the outlet's own feed. Check the original for its byline.

TIME · collected 2026-11-12 · by Alice Park

Quick Summary

Stéphane Bancel, CEO of Moderna, discusses the company’s transformation of mRNA technology from a dismissed concept to a platform for developing new medical treatments. Fifteen years ago, Bancel was skeptical about mRNA’s potential, but now Moderna’s mRNA COVID vaccine alone saved an estimated 2 million lives and earned the company $46 billion. Recent developments include the approval of an mRNA flu shot and a cancer vaccine developed in collaboration with Merck, showing mRNA’s versatility in various medical applications.
Written by AI on 2026-11-15, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

As of the latest reports, Moderna's CEO, Stéphane Bancel, is celebrating a significant milestone in the company's development of mRNA-based cancer vaccines. In October 2026, Bancel was reflecting on the company's journey from skepticism to innovation, noting that just fifteen years ago, the use of mRNA as a drug was considered impractical by many in the scientific community. Moderna has since transformed mRNA into a viable platform for medical treatments, with the company's first mRNA cancer vaccine showing promising results. The National Cancer Institute has also launched a $200 million fundraising initiative to support mRNA cancer vaccine trials, further validating the technology's potential. Moderna's advancements in this area mark a significant shift in the biotech industry's approach to drug development.

Written for “mRNA Technology Advances” on 2026-11-18, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

mRNA Technology Advances
Technology · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
193
sentences that state something as happening or true
Uncertain
9%
18 of 193 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
TIME's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Technology
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-15 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

TIME · 1023 article(s) · 2 correction(s) detected
Running correction rate · 2 correction(s)

Who wrote this

Alice Park
9 article(s) here · 1 carrying a prediction
A calculation that takes into account a person’s weight and height, BMI is supposed to reflect how much excess fat a person might be carrying and give doctors a sense of a patient's risk for obesity-related health conditions.
2026-11-13 · assertive framing · Why BMI Is Not the Best Measure of Health
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke.
On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
2026-11-12 · assertive framing · The Next Chapter of mRNA
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
Immune-based treatments for cancer have become the biggest new advance in tackling tumors, and the latest approval could make a big difference for some people with rectal cancer.
The scientists used a modified version of a reprogramming strategy that earned a Nobel Prize in 2012 for turning mature, adult cells back to an embryonic-like state from which they could become any of the cells in the body—including healthy new versions of diseased or older cells.
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.
In a new study published in Science, researchers report that for some of those cases, an inherited genetic mutation might be involved.
Also by Alice Park
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 9 articles by Alice Park →

Topics

Cambridge Intismeran Mass. Merck Moderna

Subjects

Bancel PERSON · 9× Moderna ORG · 6× Merck ORG · 2× Cambridge ORG · 1× Marseilles GPE · 1× Mass. GPE · 1× Stéphane Bancel PERSON · 1× TIME ORG · 1×

Narrative

Earlier this year, the National Cancer Institute launched a $200 million fundraising initiative to support mRNA cancer-vaccine trials, and in 2024, MSK created the Olayan Center for Cancer Vaccines to make personalized mRNA vaccines like intismeran from start to finish—beginning with genetically sequencing patients’ tumors, to generating the mRNA sequences targeting their cancer, to working with manufacturers to make the vaccine, to administering them.
framing: assertive · carried by 1 article(s) · first seen 2026-11-15
On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
2026-11-15 · TIME
The Next Chapter of mRNA · assertive framing

Claims (193 extracted, 18 hedged)

On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public. asserted
results → sit → vaccine
He’s recounting the biotech’s rocky road turning an unproven, scientifically dismissed approach—using messenger RNA, or mRNA, the genetic code that instructs cells to make proteins—into a platform for producing new categories of medicines. asserted
that → recount → medicines
Fifteen years ago, Bancel had his doubts. asserted
Bancel → have → doubts
At the time, there were no approved mRNA-based products on the market, and most scientists would have agreed that mRNA was too unstable to form the basis of a new class of medical treatments. asserted
mRNA → be → treatments
In fact, the entire biotech industry had bet—successfully—on manipulating another, more reliable genetic material: DNA. asserted
industry → bet → material
“It was crazy to think of using mRNA as a drug,” Bancel reflects. asserted
Bancel → think → drug
But that was before a fateful meeting forced him to look at the genetic material in a different way, and realize that with the right manipulation, mRNA provided a way to make drugs that were never possible with existing strategies. asserted
that → force → strategies
Now, he believes that nearly any protein drug made today with existing, recombinant DNA technology can also be made using mRNA. asserted
drug → believe → mRNA
The company’s goal isn’t to follow the usual road map and make one type of drug for one disease at a time, but to build a new platform from which a variety of different treatments can be developed in a plug-and-play scenario—similar to how the computer-technology industry is built on the foundational hardware and operating systems around which a whole universe of software has blossomed. asserted
universe → follow → software
“mRNA is the information molecule, so if you find the way to safely and effectively get it into the right cells, you can unlock a lot of medicines to help people’s suffering,” says Bancel. asserted
Bancel → find → suffering
Moderna’s mRNA COVID vaccine saved an estimated 2 million lives globally—while earning the company $46 billion—from 2021 to 2024. asserted
vaccine → save → 2024
This fall, people are getting its newly approved mRNA flu shot, the first of its kind. asserted
people → get → kind
And in October, Moderna announced with Merck that their mRNA approach also worked to stimulate the immune system to fight cancer—creating a therapeutic vaccine, rather than a preventative one. asserted
approach → announce → one
Intismeran, combined with one of Merck’s drugs, successfully kept melanoma from recurring in a group of patients with mid- to late-stage disease. asserted
Intismeran → combine → disease
By the end of the year, Bancel says, he expects to unveil similarly encouraging results from Moderna’s first mRNA therapy for a rare disease. asserted
he → say → disease
In just over a decade, mRNA has gone from molecular misfit to biomedical golden child, in no small part because of Bancel’s efforts at Moderna to prove the naysayers wrong. asserted
naysayers → go → Moderna
“At the beginning, it was either zero drugs, or we find a way to climb this mRNA mountain and make a lot of drugs,” says Bancel. asserted
Bancel → find → drugs
Consider vaccines, where mRNA is quickly becoming the preferred technology for its speed. asserted
mRNA → consider → speed
Scientists at Moderna can create a vaccine against any pathogen within six to eight weeks—far faster than it takes to then conduct the human studies required by regulatory agencies to establish a therapy’s safety and efficacy. asserted
it → create → safety
Cancer researchers hope to harness that speed with customized mRNA vaccines like intismeran. asserted
researchers → hope → intismeran
That’s what Bancel saw in mRNA more than a decade ago: an untapped vein of therapeutic ore. asserted
Bancel → ’ → ore
With mRNA, once it’s properly instructed to make the right proteins to fight a virus, fix a genetic disease, or tackle a tumor, the human body becomes its own treatment factory. asserted
body → instruct → tumor
Over a series of interviews with TIME spanning several years, Bancel unveiled the story of how a startup betting on an untested technology came to sit at the same table as decades-old pharmaceutical giants, and now holds the key to a transformative platform that could redesign treatments in three critical areas: infectious diseases, rare diseases, and cancer. uncertain
that → span → areas
Born in Marseilles, Bancel grew up with a strong interest in math and science, fueled in part by his father, an engineer who was always fixing things around the house. asserted
who → bear → house
“We used to sail in the summer, and one summer my brother and father and I sailed from Marseilles to Mallorca—a two-day trip—and the engine broke in the middle of the water in the middle of the night,” he says. asserted
he → use → night
“I remember we were holding the flashlight above him, and he was fixing the engine by himself.” asserted
he → remember → himself
Bancel was pursuing a degree in chemical engineering at Ecole Centrale Paris when, on a whim, he took a genetics class at the university next door and “fell in love with genetics,” he says. asserted
he → pursue → genetics
He went on to earn a master’s in chemical engineering at the University of Minnesota and an M.B.A. from Harvard Business School before working at Eli Lilly in Indianapolis for six years, mostly in manufacturing. asserted
He → go → manufacturing
In 2006, he became CEO of the French diagnostics company bioMérieux. asserted
he → become → company
He was working in the company’s Boston office in 2011 when he got a call from his friend Noubar Afeyan, founder of Flagship Pioneering, a venture-capital firm and health-startup incubator. asserted
he → work → Pioneering
Bancel served on the boards of several of Afeyan’s startups and had already turned down multiple offers to lead some of the new companies. asserted
Bancel → serve → companies
But Afeyan thought he finally had one that might entice his friend. uncertain
that → think → friend
Afeyan had been approached by a trio of scientists with the idea for a company to develop new treatments from mRNA. asserted
Afeyan → approach → mRNA
He showed Bancel data from a handful of mice that had been injected with human mRNA to make a human protein. asserted
that → show → protein
“I’m like, ‘This is impossible, because everything we learned in biology is that if you inject mRNA, you create an immune response,’” says Bancel. asserted
Bancel → ’m → response
But what if it worked? asserted
it → work → ?
Afeyan persisted. asserted
Afeyan → persist → ?
What would it mean? asserted
it → mean → What
“I said, if it works, you’re going to be able to make hundreds, maybe thousands of medicines that you cannot using [current] biotech technology,” says Bancel. asserted
Bancel → say → technology
Up to that point, the biotech industry was focused on manipulating DNA and making products to work on molecules that cells secreted—all in cell cultures using bacteria or viruses that were genetically engineered to produce the molecule in question. asserted
that → focus → question
…and 153 more, not listed.
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support